Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes. 2004

Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
Department of Medicine, Gene Transfer and Somatic Cell Engineering Laboratory, Immunology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. rivierei@mskcc.org

The genetic modification of T lymphocytes is an important methodology for investigating T-cell biology and bears great promise as a possible strategy for cancer immunotherapy. Several genetic approaches under evaluation aim to facilitate and increase the recognition of tumor antigens, enhance antitumor activities, and counteract the multiple mechanisms responsible for tumor immune evasion in vivo. T cells can also be engineered in an attempt to control their homing, to increase the safety of adoptive T-cell therapies, and express markers that can be tracked by noninvasive imaging technologies.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015202 Protein Engineering Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes. Genetic Engineering of Proteins,Genetic Engineering, Protein,Proteins, Genetic Engineering,Engineering, Protein,Engineering, Protein Genetic,Protein Genetic Engineering
D037182 T-Cell Antigen Receptor Specificity The property of the T-CELL RECEPTOR which enables it to react with some antigens and not others. The specificity is derived from the structure of the receptor's variable region which has the ability to recognize certain antigens in conjunction with the MAJOR HISTOCOMPATIBILITY COMPLEX molecule. T-Cell Immunologic Specificity,T-Cell Specificity,T-Cell Receptor Specificity,Immunologic Specificity, T-Cell,Specificity, T-Cell,Specificity, T-Cell Immunologic,Specificity, T-Cell Receptor,T Cell Antigen Receptor Specificity,T Cell Immunologic Specificity,T Cell Receptor Specificity,T Cell Specificity

Related Publications

Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
July 1991, Cancer cells (Cold Spring Harbor, N.Y. : 1989),
Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
June 2012, The journal of gene medicine,
Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
January 1997, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine,
Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
January 2014, Advances in experimental medicine and biology,
Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
November 2009, Cancer gene therapy,
Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
January 1984, Journal of biological response modifiers,
Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
May 2014, Clinical & translational immunology,
Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
January 2021, Frontiers in oncology,
Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
May 2013, Neoplasia (New York, N.Y.),
Isabelle Rivière, and Michel Sadelain, and Renier J Brentjens
April 2015, Disease models & mechanisms,
Copied contents to your clipboard!